Schizophrenia (SZ) and bipolar disorder (BD) share numerous clinical and biological features as well as environmental risk factors that may be associated with altered DNA methylation.
Introduction
Owing to recent advances in genomic technologies and collaboration among global consortia, schizophrenia (SZ) and bipolar disorder (BD) have been shown to share a significant proportion of genetic liability (Hamshere et al., 2011; Ivleva et al., 2010; Purcell et al., 2009) . For example, the degree to which multiple sites of genetic variation contribute to risk for SZ and BD can be summarised using 'polygenic risk scores', calculated as the sum of alleles associated with a particular trait, weighted by their respective effect sizes (Purcell et al., 2009) . While the majority of these genetic variants would individually fail to reach even nominal levels of statistical significance, collectively they may account for a significant proportion of the variance in manifestation of SZ and BD (Purcell et al., 2009 ). However, there remains a significant amount of unexplained variance in shared genetic and environmental risk for these disorders (Lichtenstein et al., 2009 ), some of which may be accounted for by epigenetic processes associated with shared environmental risk factors such as childhood trauma, cannabis use, obstetric complications (Bourque et al., 2011; Buoli et al., 2016; Cannon et al., 2002; Kraan et al., 2016; Laursen et al., 2007) .
Epigenetic processes, such as DNA methylation, refer to functionally significant alterations in the genome that do not alter the nucleotide sequence (Hannon et al., 2016; Montano et al., 2016; Pries et al., 2017) . DNA methylation involves the addition of a methylgroup to the carbon-5 position of a cytosine residue (Razin and Cedar, 1991) : this may be associated with increased or decreased gene expression depending on the genomic region in which it occurs (Jones, 2012; Watkeys et al., 2018) . Both candidate-and genome-wide studies have revealed differential methylation of various sites in SZ (Hannon et al., 2016; Montano et al., 2016; Ruzicka et al., 2015; Yoshino et al., 2016) , with some studies suggesting overlapping patterns of DNA methylation in BD (Dempster et al., 2011; Sugawara Poly-methylomic Profile Scores for schizophrenia 4 et al., 2018), although there have been few replications at individual CpG sites (Pries et al., 2017; Teroganova et al., 2016) .
A recently published epigenome-wide association study (EWAS) (Hannon et al., 2016 ) of blood-derived DNA methylation patterns reported 14 differentially methylated CpG sites that were robustly associated with SZ in both a large discovery sample (comprising 353 SZ cases and 322 healthy controls) and a replication sample (comprising 414 SZ cases and 433 healthy controls), at a stringent significance level (p < 1×10 -7 ). A larger number of CpGs (n=213) were associated with SZ in both the discovery and replication case-control samples at a more liberal significance threshold (p < 1×10 -5 ). (Montano et al., 2016) .
In this study, we adapted methodology used to calculate PRS from GWAS summary statistics, to estimate a series of poly-methylomic profile scores (PMPSs) for SZ. The calculation of these scores was based on discovery effect sizes of individual differentially methylated CpG sites at various p-value thresholds as reported by Hannon et al. (2016) . We then established the extent to which these PMPSs were associated with an independent sample of cases with SZ, BD, and the combined SZ-BD group (each compared to healthy controls; HC), and directly compared PMPSs between SZ and BD. We also explored (Loughland et al., 2010) , and the Sydney BD Clinic (Mitchell et al., 2009) . Healthy controls were recruited from the local community. Study exclusion criteria included current neurological disorder, current substance abuse or dependence, and/or electroconvulsive treatment in the past six months. Healthy controls were also required to have no lifetime history of a DSM-IV Axis-I diagnosis (American Psychiatric Association, 1994) confirmed using the Mini-International Neuropsychiatric Interview (Sheehan et al., 1998) , and no history of psychotic disorders among first-degree biological relatives.
Cognitive and symptom measures
Estimates of premorbid and current intelligence quotients (IQ) were calculated using the Wechsler Test of Adult Reading (Wechsler, 2001) , and the Wechsler Abbreviated Scale of Intelligence (Wechsler, 1999) , respectively. The Scales for the Assessment of Positive Symptoms (SAPS) and Negative Symptoms (SANS) were used to assess symptom severity (Andreasen, 1984a, b (ii) >10% of samples demonstrated less than 3 beads at a given probe (n = 141), or (iii) the probe was previously demonstrated to be cross-reactive (n = 29 233) (Chen et al., 2013) .
After application of these QC procedures, 456 041 CpG sites remained for analysis in the 171 participants. However, in the current study we only included the 1051 independent CpG sites demonstrating a replication p-value < 0.5 in Hannon et al.'s (Hannon et al., 2016 ) first replication cohort.
Blood cell count estimates were derived from methylation data for Bcells, CD4T, CD8T, granulocytes, monocytes, and natural killer cells using meffil's gse35069 profile references. Shinymethyl (Fortin et al., 2014) was used to conduct principle components analysis with the final QCed data. We found two components significantly associated with ethnicity (p < 0.05), which were included as covariates in all subsequent analysis.
Poly-Methylomic Profile Score (PMPS)
PMPSs were calculated utilising data from multiple CpG sites previously reported as demonstrating an association with SZ (Hannon et al., 2016) , weighted on the basis of discovery sample effect sizes. Sites were included in the PMPSs if they replicated across the two cohorts tested by Hannon et al. (2016) at five different p-value thresholds (1×10 -7 , 1×10 -5 , 0.001, 0.05, 0.5). The use of multiple p-value thresholds is standard in the construction of polygenic risk scores, in order to identify the threshold that enables optimal prediction (Purcell et al., 2009 ). The five p-value thresholds included 14, 210, 359, 684, and 1051 CpG sites in each PMPS, respectively. The first two scores were calculated based on CpG sites which replicated at their respective p-value threshold across both the discovery and first replication cohort. In contrast, the final three PMPSs were calculated based on sites that evidenced at least a discovery threshold (p < 1×10 -5 ) association with schizophrenia and replicated at each of the three thresholds listed above, respectively (Hannon et al., 2016) .
Each PMPS score was calculated using previously described methods (Shah et al., 2015) as the sum of weighted beta values associated with SZ, or:
Where PMPSi is the polymethylomic profile score for the i th participant, Bij is the beta value for the i th participant at the j th CpG site, and ∆j is the effect size for the j th CpG site.
To ensure that each PMPS was not inflated by correlated methylation among CpGs, the independence of CpG sites meeting thresholds for inclusion in any PMPS was assessed via correlation analyses. In the event that two or more CpG sites within 500 base-pairs ( (2016) was retained for PMPS calculation, whilst the other correlated sites (n=10) were excluded (see Supplementary Table 1 ) (Huynh et al., 2013; Ong and Holbrook, 2013; Shah et al., 2015) .
As smoking behaviour influences methylation (Zeilinger et al., 2013) , we used the method described above to estimate a methylation smoking score, using smoking-related methylation effect sizes for CpG sites demonstrating a significant replicated association with smoking status (p-value < 5 x 10 -5 ) reported previously (Zeilinger et al., 2013) . We validated this score using smoking data collected for our clinical participants; the smoking score was significantly associated with both lifetime smoking (B = 0.880, OR = 2.410, p = 6.49 x 10 -5 )
and Fagerstrom test for nicotine dependency (Heatherton et al., 1991) A series of logistic regression analyses were then performed to assess if the PMPSs were associated with: (i) SZ (relative to HC); (ii) BD (relative to HC); (iii) the combined BD and SZ group (relative to HC); and (iv) SZ (relative to BD). The PMPSs were converted to zscores before analysis so that regression coefficients and effect sizes would be comparable between models. FDR correction was applied across the five PMPSs assessed within each group comparison. In addition, two linear regression analyses were used to assess if the optimal PMPS was associated with SAPS and SANS global subscale scores respectively.
To investigate any potential confounding effects of medication, we ran three linear regression models (one model each for BD, SZ, and the combined SZ-BD cohort), with the PMPS that explained the most variance in SZ as the dependent variable, and imipramine (antidepressant) equivalency dosage, chlorpromazine (antipsychotic) equivalency dosage, and mood stabiliser usage included as predictors in addition to covariates used in all other analyses.
Results
Demographic information for included participants is summarised in 
PMPS model comparisons in association with SZ
All five PMPSs were significantly associated with SZ relative to HC both before and after FDR correction (see Table 2 ). All models explained a similar amount of the variance in SZ (58-60%), however models incorporating PMPSs based on more liberal p-value inclusion thresholds tended to explain less of the variance (see Table 2 ). The PMPS that explained the greatest amount of variance in SZ diagnosis incorporated the 14 CpG sites which were those most robustly associated with SZ across both discovery and replication samples from 
SZ-PMPS in association with BD and the cross-disorder sample
In contrast to the SZ-HC PMPS models (described above), models comparing BD and the combined "psychosis spectrum" group (SZ + BD = 116 cases) to HCs, explained considerably less of the variance (39-41% and 31-33%, respectively). Furthermore, none of the SZ PMPSs within these models were significantly associated with a diagnosis of BD (relative to HCs), nor were they significantly associated with the combined "psychosis spectrum" group relative to HCs either before or after FDR correction. Conversely, a considerable degree of the variance in BD versus SZ status was accounted for by the PMPS models (51-53%). While there was no significant difference between BD and SZ participants on the PMPS calculated at the most stringent p-value threshold (p < 1 x 10 -7 ) (B = 0.852, OR = 2.345, 95% CI = 0.970-5.666, p = 0.055) all other PMPS scores were significantly elevated in SZ relative to BD. However, none of these associations withstood FDR correction (see Table 2 ).
Associations between optimal PMPS and positive and negative symptoms of psychosis
There were no relationships between the optimal PMPS and any subscales of the SAPS and SANS, respectively (see Table 3 ).
Potential effects of medication on PMPS scores
Irrespective of clinical group (SZ, BD, or cross-diagnostic "psychosis spectrum" group), all linear regression analyses indicated that medication usage was not significantly associated with the optimal PMPS (all p > 0.05; see Table 4 ).
Discussion
Here we demonstrate the construction of a Poly-Methylomic Profile Score for schizophrenia based on differentially methylated CpG sites reported in a recent EWAS in schizophrenia (2016); we demonstrate significantly higher scores in an independent schizophrenia sample, relative to healthy controls, at both stringent and increasingly liberal thresholds of significance. Although we found little evidence for significant differences in methylation at those individual CpG sites in this small schizophrenia sample, likely due to limited power, there was 100% consistency in the direction of DNA hyper-/hypo-methylation in our schizophrenia sample among the 14 CpG sites previously reported as most strongly associated with schizophrenia (Hannon et al., 2016) . Interestingly, schizophrenia PMPSs were not associated with BD or the combined psychosis group compared to healthy controls, suggesting that the SZ-derived PMPS may reflect distinct pathophysiology in SZ.
Furthermore, whilst the PMPS differences between SZ and BD were not significant after FDR correction, these associations were only just above the threshold of statistical significance. Whilst it is possible that this indicates shared methylation patterns between SZ and BD, it is also possible that our study was underpowered to detect true differences in the methylation profiles between SZ and BD.
The capacity to demonstrate associations between the constructed poly-methylomic scores and schizophrenia is consistent with the idea that methylation changes in schizophrenia span multiple CpG sites of small effect throughout the genome, and that collectively, the summed effects across multiple CpG sites should explain a larger proportion of the variance in the manifestation of schizophrenia than individual CpG sites alone.
Notably, the amount of variance explained by the PMPSs decreased as increasingly liberal pvalue thresholds were adopted for score calculation. This stands in stark contrast to genetic polygenic risk scores, which tend to explain more of the variance when more liberal p-value thresholds are utilised (Purcell et al., 2009) . This difference may reflect the smaller EWAS cohorts compared to those used to generate polygenic risk scores for schizophrenia (Purcell et al., 2009) . However, additional consideration should also be given to the increased extent to which DNA methylation is susceptible to confounding factors. That is, whilst genetic sequence variants are inherited directly from parents and remain stable across the lifespan (except in the case of de novo events), epigenetic processes are susceptible to environmental modification and change over time (Dempster et al., 2013) . These factors make it inappropriate to characterise a trait-associated methylation score as indexing risk for the trait in question. Rather, any such score might be instead regarded as summarising the methylation profile associated with a given trait. Indeed, such scores have already been calculated for phenotypes such as body-mass index (BMI) and environmental exposures such as smoking status, education, and alcohol consumption (Elliott et al., 2014; Hamilton et al., 2018; McCartney et al., 2018) . Our study reflects the first attempt to derive such scores from methylome-wide CpG data for established schizophrenia. Application of this profile to firstepisode psychosis samples, and the further derivation of PMPSs from EWASs conducted in first-episode psychosis and other medication naive high-risk samples, will be useful to understand its potential biological relevance to disease risk and the emerging pathophysiology of schizophrenia.
Interestingly, none of the SZ-derived PMPS scores were associated with BD or the cross-disorder psychosis group relative to HCs, suggesting that the methylation patterns summarised by these scores may reflect distinct schizophrenia pathophysiology. This was somewhat unexpected given increasing evidence of biological overlap between schizophrenia and BD (Dempster et al., 2011; Ivleva et al., 2010; Laursen et al., 2007; Purcell et al., 2009; Sugawara et al., 2018) . Furthermore, whilst PMPSs were not significantly elevated in SZ compared to BD after correcting for multiple testing, this could reflect lack of power. Larger discovery EWASs may be required to identify CpGs that are differentially methylated in both conditions. It would also be interesting to determine if a PMPS calculated using discovery data from a BD cohort is associated with both BD and SZ, however large discovery EWAS datasets in bipolar disorder are currently lacking.
Several limitations should be considered when interpreting these results. First, the reference profile used for estimating cellular composition was based on a small sample of men (Reinius et al., 2012) . Whilst this method is widely used, questions remain regarding the validity of this measure as a means of estimating cellular composition in the broader population. Other potential sources of variation in DNA methylation include participants' smoking behaviours (Zeilinger et al., 2013) and body mass index (BMI) (McCartney et al., 2018) . We partially addressed this by estimating a methylation-based smoking score for use as a covariate (Elliott et al., 2014) , since smoking status can be accurately estimated using methylation profile scores (Elliott et al., 2014) . However, a methylation-derived score of BMI was not estimated, as there is substantially less reliability where BMI estimation is concerned (McCartney et al., 2018) , and phenotypic BMI data was not available for our sample.
Regarding potential medication effects, we saw no significant associations between PMPS for schizophrenia and antipsychotic and antidepressant dosages, or mood stabiliser use, but caution that further research in medication-naïve cohorts is warranted. It is also important to note that the tissue specificity inherent to DNA methylation patterns (Davies et al., 2012; Murphy et al., 2005; van den Oord et al., 2016; Walton et al., 2016; Xin et al., 2010) which are highly influenced by cellular composition (Jaffe and Irizarry, 2014) , limits the generalisability of methylation patterns obtained from blood. Replicating the methods described here using discovery/replication cohorts derived from brain tissue will be important to understand the significance of methylation patterns over the course of illness.
In conclusion, we have developed a novel method for calculating a poly-methylomic profile of schizophrenia based on published EWAS data; all profile scores derived at various Boxplots showing group differences on the PMPS calculated at the most stringent p-value threshold (p 1 x 10 -7 ) between: A) schizophrenia cases and healthy controls, B) bipolar disorder cases and healthy controls, C) combined clinical cases (SZ+BD) and healthy controls, and D) bipolar disorder and schizophrenia. 
